The EMBL Imaging Centre has received €7 million in support from Boehringer Ingelheim Stiftung to further advance its cutting-edge imaging technologies.
ADVERTISEMENT
Biomanufacturing promises domestic, sustainable, sovereign and resilient production. Capacities are trapped in outdated scale-up processes. SPRIND urges investment and disruptive innovation to propel biomanufacturing. Demands are decentralised, non-sterile & continuous biomanufacturing capabilities.
Resilience and quality connections define Chemspec Europe 2025.
A landmark study in the UK shows that mitochondrial replacement therapy can prevent babies from inheriting diseases caused by mutant mitochondria.
That deserves a closer look: The recently announced partnership between Axxam S.p.A., a leading provider of integrated early discovery services, and Molecular Health GmbH, a pioneer in AI-powered data solutions for pharmaceutical R&D, is more than a standard collaboration. It exemplifies the convergence of consolidated in-vitro biology-led drug discovery with modern, data-intelligent drug development methodologies. As an example for breaking the silos of clinical and preclinical target validation.
Spain’s biotech sector drives innovation, economic growth, and scientific excellence. With strong R&D investment, global research impact, and a leading role in gender equality, it’s a key player in health, sustainability, and strategic autonomy. BIOSPAIN 2025 in Barcelona will showcase its potential and connect global biotech leaders.
Pichia pastoris (syn. Komagataella phaffii), a methylotrophic yeast, is a proven platform for pharmaceutical protein production. However, its potential reaches far beyond. As a reliable, scalable, and cost-efficient platform for recombinant protein expression, Pichia is equally suited for industrial enzymes, food & feed, diagnostics, and biomaterials.
In today’s rapidly evolving world, adapting to demand volatilities while ensuring uninterrupted supply of biological medicines is more critical than ever. At Boehringer Ingelheim, our global biopharmaceutical network delivers flexibility, resilience, and reliability. By leveraging harmonised procedures, standardised setups, and innovative logistics, we ensure the biologics we produce reach those in need – even during unexpected challenges.
In the life sciences industry, Quality Management (QM) has long been synonymous with compliance: checking boxes to meet regulatory demands. But that definition no longer holds up. Today, QM must do much more than ensure compliance; it needs to enable speed, scalability, and sustained innovation across complex, global operations. To do that, prominent gaps need to be filled.
It all began with a view from the window of the 15th floor of Bayer’s site in Berlin, reminiscent of Boston before it became one of the most important biotech hotspots in the world. This inspired the vision of developing the Bayer Campus into “Boston an der Spree” – a vibrant healthcare campus that fosters collaboration and innovation.